Loss holds flat year-over-year. Cullinan Therapeutics reported a loss of $0.77 per share for Q4 2025. The biotechnology company posted a net loss of $50.7 million and an operating loss of $55.3 million for the quarter. The company generated no revenue during the period, consistent with its pre-commercial stage as a clinical-stage biopharmaceutical company.
Revenue remains absent. Cullinan Therapeutics recorded zero revenue in Q4 2025, unchanged from the year-ago quarter when revenue was also zero. The company has not generated product revenue in any of the past five quarters, reflecting its focus on advancing clinical-stage oncology and autoimmune programs through development rather than commercialization. Trading volume reached 864,736 shares on the report date, with the stock closing at $15.74.
Sequential burn rate unchanged. The $0.73 per share loss in Q4 2025 matched the prior quarter’s $0.73 loss, suggesting stable operating expenses quarter-over-quarter. The company’s loss per share has ranged from $0.77 to $1.07 over the past five quarters, with Q2 2025 representing the peak burn rate. With 59.1 million shares outstanding and a market capitalization of $904 million, investors are pricing in significant pipeline value despite the ongoing cash consumption.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year first appeared on Alphastreet.
